Global Retinal Detachment- Market

Retinal Detachment- Comprehensive Study by Type (Rhegmatogenous, Tractional, Exudative), Treatment Type (Surgical Others, Laser Therapy, Cryopexy, Others), End User (Hospitals, Speciality centre, Clinics, Others) Players and Region - Global Market Outlook to 2030

Retinal Detachment- Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Retinal Detachment- Market Overview:
Retinal detachment is a serious eye problem in that the retina is pulled away from the normal position at the back of the eyes. The symptoms of retinal detachment are sudden increases in floaters, flashes of light in the eyes, darkening of side vision, darkening of the shadow covering part of vision, etc. Retinal detachment includes various treatments such as laser therapy, pneumatic (gas bubble) retinopexy, scleral buckle, and vitrectomy. Advancements in diagnostic tools and imaging technologies can improve the early detection and treatment of retinal detachment; this may be the factor that accelerated the growth of this market.

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
The trend towards minimally invasive procedures continues to grow in the retinal detachment industry

Market Growth Drivers:
Growing development of innovative and effective treatments for retinal detachment, such as new surgical techniques. and Public awareness and education campaigns can lead to earlier detection and treatment, potentially influencing the market growth.

Challenges:
Limited awareness among the general population and even healthcare professionals. and Shortage of trained Ophthalmologists

Restraints:
High cost associated with retinal detachment treatment, such as surgical procedures.

Opportunities:
Adoption of advanced technologies such as robotic-assisted surgery, artificial intelligence for diagnostics.

Competitive Landscape:
The global market is highly competitive and consists of a limited number of providers who compete with each other. The companies are implementing strategic activities such as acquisition and mergers along with collaboration with companies in other industries to help them in improving sustenance and maintaining their competitive advantages
Some of the key players profiled in the report are Alcon Laboratories Inc. (Switzerland), Bausch Health Companies Inc. (Canada), Peek Vision Ltd. (United Kingdom), NEUROVISION IMAGING (United States), NIDEK CO., LTD. (Japan), Haag-Streit Group (Switzerland), Johnson & Johnson Vision Care Inc. (United States), Novartis AG (Switzerland), Topcon Corporation (Japan), KARL STORZ SE & Co. KG (Germany), Centervue SpA, (Italy), Eyenuk Inc (United States), Imagine Eyes (France), HealPros, LLC. (United States), Optos (United Kingdom), Zeiss Group (Germany) and Biogen (United States). Considering Market by Type, the sub-segment i.e. Rhegmatogenous will boost the Retinal Detachment- market. Considering Market by Treatment Type, the sub-segment i.e. Surgical Others will boost the Retinal Detachment- market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Retinal Detachment- market.

Latest Market Insights:
In April 2022, Carl Zeiss Meditec acquired of two manufacturers of surgical instruments (Kogent Surgical, LLC and Katalyst Surgical, LLC) to further strengthen its positioning as a solution provider. This is a strategically important acquisition for ZEISS Medical Technology. Acquisition expects to scale the businesses and contribute to our surgical solution offering and add recurring revenue.

In June 2022, Biogen Inc. and Samsung Bioepis Co., Ltd. launched that BYOOVIZ, a biosimilar referencing LUCENTIS (ranibizumab). The FDA approved BYOOVIZ in the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion, and myopic choroidal neovascularization.

What Can be Explored with the Retinal Detachment- Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Retinal Detachment- Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Retinal Detachment-
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Retinal Detachment- market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Retinal Detachment- market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Research organization, Government Regulatory, End-User Industry and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Rhegmatogenous
  • Tractional
  • Exudative

By Treatment Type
  • Surgical Others
  • Laser Therapy
  • Cryopexy
  • Others

By End User
  • Hospitals
  • Speciality centre
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing development of innovative and effective treatments for retinal detachment, such as new surgical techniques.
      • 3.2.2. Public awareness and education campaigns can lead to earlier detection and treatment, potentially influencing the market growth.
    • 3.3. Market Challenges
      • 3.3.1. Limited awareness among the general population and even healthcare professionals.
      • 3.3.2. Shortage of trained Ophthalmologists
    • 3.4. Market Trends
      • 3.4.1. The trend towards minimally invasive procedures continues to grow in the retinal detachment industry
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Retinal Detachment-, by Type, Treatment Type, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Retinal Detachment- (Value)
      • 5.2.1. Global Retinal Detachment- by: Treatment Type (Value)
        • 5.2.1.1. Surgical Others
        • 5.2.1.2. Laser Therapy
        • 5.2.1.3. Cryopexy
        • 5.2.1.4. Others
      • 5.2.2. Global Retinal Detachment- by: End User (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Speciality centre
        • 5.2.2.3. Clinics
        • 5.2.2.4. Others
      • 5.2.3. Global Retinal Detachment- Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Retinal Detachment-: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Alcon Laboratories Inc. (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bausch Health Companies Inc. (Canada)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Peek Vision Ltd. (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. NEUROVISION IMAGING (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. NIDEK CO., LTD. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Haag-Streit Group (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson Vision Care Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis AG (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Topcon Corporation (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. KARL STORZ SE & Co. KG (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Centervue SpA, (Italy)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Eyenuk Inc (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Imagine Eyes (France)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. HealPros, LLC. (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Optos (United Kingdom)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Zeiss Group (Germany)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Biogen (United States)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
  • 7. Global Retinal Detachment- Sale, by Type, Treatment Type, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Retinal Detachment- (Value)
      • 7.2.1. Global Retinal Detachment- by: Treatment Type (Value)
        • 7.2.1.1. Surgical Others
        • 7.2.1.2. Laser Therapy
        • 7.2.1.3. Cryopexy
        • 7.2.1.4. Others
      • 7.2.2. Global Retinal Detachment- by: End User (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Speciality centre
        • 7.2.2.3. Clinics
        • 7.2.2.4. Others
      • 7.2.3. Global Retinal Detachment- Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Retinal Detachment-: by Treatment Type(USD Million)
  • Table 2. Retinal Detachment- Surgical Others , by Region USD Million (2018-2023)
  • Table 3. Retinal Detachment- Laser Therapy , by Region USD Million (2018-2023)
  • Table 4. Retinal Detachment- Cryopexy , by Region USD Million (2018-2023)
  • Table 5. Retinal Detachment- Others , by Region USD Million (2018-2023)
  • Table 6. Retinal Detachment-: by End User(USD Million)
  • Table 7. Retinal Detachment- Hospitals , by Region USD Million (2018-2023)
  • Table 8. Retinal Detachment- Speciality centre , by Region USD Million (2018-2023)
  • Table 9. Retinal Detachment- Clinics , by Region USD Million (2018-2023)
  • Table 10. Retinal Detachment- Others , by Region USD Million (2018-2023)
  • Table 11. South America Retinal Detachment-, by Country USD Million (2018-2023)
  • Table 12. South America Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 13. South America Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 14. South America Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 15. Brazil Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 16. Brazil Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 17. Brazil Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 18. Argentina Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 19. Argentina Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 20. Argentina Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 21. Rest of South America Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 22. Rest of South America Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 23. Rest of South America Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 24. Asia Pacific Retinal Detachment-, by Country USD Million (2018-2023)
  • Table 25. Asia Pacific Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 26. Asia Pacific Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 27. Asia Pacific Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 28. China Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 29. China Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 30. China Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 31. Japan Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 32. Japan Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 33. Japan Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 34. India Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 35. India Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 36. India Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 37. South Korea Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 38. South Korea Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 39. South Korea Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 40. Taiwan Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 41. Taiwan Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 42. Taiwan Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 43. Australia Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 44. Australia Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 45. Australia Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 46. Rest of Asia-Pacific Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 49. Europe Retinal Detachment-, by Country USD Million (2018-2023)
  • Table 50. Europe Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 51. Europe Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 52. Europe Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 53. Germany Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 54. Germany Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 55. Germany Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 56. France Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 57. France Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 58. France Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 59. Italy Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 60. Italy Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 61. Italy Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 62. United Kingdom Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 63. United Kingdom Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 64. United Kingdom Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 65. Netherlands Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 66. Netherlands Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 67. Netherlands Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 68. Rest of Europe Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 69. Rest of Europe Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 70. Rest of Europe Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 71. MEA Retinal Detachment-, by Country USD Million (2018-2023)
  • Table 72. MEA Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 73. MEA Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 74. MEA Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 75. Middle East Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 76. Middle East Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 77. Middle East Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 78. Africa Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 79. Africa Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 80. Africa Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 81. North America Retinal Detachment-, by Country USD Million (2018-2023)
  • Table 82. North America Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 83. North America Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 84. North America Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 85. United States Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 86. United States Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 87. United States Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 88. Canada Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 89. Canada Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 90. Canada Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 91. Mexico Retinal Detachment-, by Type USD Million (2018-2023)
  • Table 92. Mexico Retinal Detachment-, by Treatment Type USD Million (2018-2023)
  • Table 93. Mexico Retinal Detachment-, by End User USD Million (2018-2023)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Retinal Detachment-: by Treatment Type(USD Million)
  • Table 112. Retinal Detachment- Surgical Others , by Region USD Million (2025-2030)
  • Table 113. Retinal Detachment- Laser Therapy , by Region USD Million (2025-2030)
  • Table 114. Retinal Detachment- Cryopexy , by Region USD Million (2025-2030)
  • Table 115. Retinal Detachment- Others , by Region USD Million (2025-2030)
  • Table 116. Retinal Detachment-: by End User(USD Million)
  • Table 117. Retinal Detachment- Hospitals , by Region USD Million (2025-2030)
  • Table 118. Retinal Detachment- Speciality centre , by Region USD Million (2025-2030)
  • Table 119. Retinal Detachment- Clinics , by Region USD Million (2025-2030)
  • Table 120. Retinal Detachment- Others , by Region USD Million (2025-2030)
  • Table 121. South America Retinal Detachment-, by Country USD Million (2025-2030)
  • Table 122. South America Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 123. South America Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 124. South America Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 125. Brazil Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 126. Brazil Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 127. Brazil Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 128. Argentina Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 129. Argentina Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 130. Argentina Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 131. Rest of South America Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 132. Rest of South America Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 133. Rest of South America Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 134. Asia Pacific Retinal Detachment-, by Country USD Million (2025-2030)
  • Table 135. Asia Pacific Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 136. Asia Pacific Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 137. Asia Pacific Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 138. China Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 139. China Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 140. China Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 141. Japan Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 142. Japan Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 143. Japan Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 144. India Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 145. India Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 146. India Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 147. South Korea Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 148. South Korea Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 149. South Korea Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 150. Taiwan Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 151. Taiwan Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 152. Taiwan Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 153. Australia Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 154. Australia Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 155. Australia Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 158. Rest of Asia-Pacific Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 159. Europe Retinal Detachment-, by Country USD Million (2025-2030)
  • Table 160. Europe Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 161. Europe Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 162. Europe Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 163. Germany Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 164. Germany Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 165. Germany Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 166. France Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 167. France Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 168. France Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 169. Italy Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 170. Italy Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 171. Italy Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 172. United Kingdom Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 173. United Kingdom Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 174. United Kingdom Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 175. Netherlands Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 176. Netherlands Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 177. Netherlands Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 178. Rest of Europe Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 179. Rest of Europe Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 180. Rest of Europe Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 181. MEA Retinal Detachment-, by Country USD Million (2025-2030)
  • Table 182. MEA Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 183. MEA Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 184. MEA Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 185. Middle East Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 186. Middle East Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 187. Middle East Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 188. Africa Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 189. Africa Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 190. Africa Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 191. North America Retinal Detachment-, by Country USD Million (2025-2030)
  • Table 192. North America Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 193. North America Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 194. North America Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 195. United States Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 196. United States Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 197. United States Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 198. Canada Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 199. Canada Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 200. Canada Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 201. Mexico Retinal Detachment-, by Type USD Million (2025-2030)
  • Table 202. Mexico Retinal Detachment-, by Treatment Type USD Million (2025-2030)
  • Table 203. Mexico Retinal Detachment-, by End User USD Million (2025-2030)
  • Table 204. Research Programs/Design for This Report
  • Table 205. Key Data Information from Secondary Sources
  • Table 206. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Retinal Detachment-: by Treatment Type USD Million (2018-2023)
  • Figure 5. Global Retinal Detachment-: by End User USD Million (2018-2023)
  • Figure 6. South America Retinal Detachment- Share (%), by Country
  • Figure 7. Asia Pacific Retinal Detachment- Share (%), by Country
  • Figure 8. Europe Retinal Detachment- Share (%), by Country
  • Figure 9. MEA Retinal Detachment- Share (%), by Country
  • Figure 10. North America Retinal Detachment- Share (%), by Country
  • Figure 11. Global Retinal Detachment- share by Players 2023 (%)
  • Figure 12. Global Retinal Detachment- share by Players (Top 3) 2023(%)
  • Figure 13. Global Retinal Detachment- share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Alcon Laboratories Inc. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 16. Alcon Laboratories Inc. (Switzerland) Revenue: by Geography 2023
  • Figure 17. Bausch Health Companies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 18. Bausch Health Companies Inc. (Canada) Revenue: by Geography 2023
  • Figure 19. Peek Vision Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. Peek Vision Ltd. (United Kingdom) Revenue: by Geography 2023
  • Figure 21. NEUROVISION IMAGING (United States) Revenue, Net Income and Gross profit
  • Figure 22. NEUROVISION IMAGING (United States) Revenue: by Geography 2023
  • Figure 23. NIDEK CO., LTD. (Japan) Revenue, Net Income and Gross profit
  • Figure 24. NIDEK CO., LTD. (Japan) Revenue: by Geography 2023
  • Figure 25. Haag-Streit Group (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Haag-Streit Group (Switzerland) Revenue: by Geography 2023
  • Figure 27. Johnson & Johnson Vision Care Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Johnson & Johnson Vision Care Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 31. Topcon Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Topcon Corporation (Japan) Revenue: by Geography 2023
  • Figure 33. KARL STORZ SE & Co. KG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. KARL STORZ SE & Co. KG (Germany) Revenue: by Geography 2023
  • Figure 35. Centervue SpA, (Italy) Revenue, Net Income and Gross profit
  • Figure 36. Centervue SpA, (Italy) Revenue: by Geography 2023
  • Figure 37. Eyenuk Inc (United States) Revenue, Net Income and Gross profit
  • Figure 38. Eyenuk Inc (United States) Revenue: by Geography 2023
  • Figure 39. Imagine Eyes (France) Revenue, Net Income and Gross profit
  • Figure 40. Imagine Eyes (France) Revenue: by Geography 2023
  • Figure 41. HealPros, LLC. (United States) Revenue, Net Income and Gross profit
  • Figure 42. HealPros, LLC. (United States) Revenue: by Geography 2023
  • Figure 43. Optos (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 44. Optos (United Kingdom) Revenue: by Geography 2023
  • Figure 45. Zeiss Group (Germany) Revenue, Net Income and Gross profit
  • Figure 46. Zeiss Group (Germany) Revenue: by Geography 2023
  • Figure 47. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 48. Biogen (United States) Revenue: by Geography 2023
  • Figure 49. Global Retinal Detachment-: by Treatment Type USD Million (2025-2030)
  • Figure 50. Global Retinal Detachment-: by End User USD Million (2025-2030)
  • Figure 51. South America Retinal Detachment- Share (%), by Country
  • Figure 52. Asia Pacific Retinal Detachment- Share (%), by Country
  • Figure 53. Europe Retinal Detachment- Share (%), by Country
  • Figure 54. MEA Retinal Detachment- Share (%), by Country
  • Figure 55. North America Retinal Detachment- Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Alcon Laboratories Inc. (Switzerland)
  • Bausch Health Companies Inc. (Canada)
  • Peek Vision Ltd. (United Kingdom)
  • NEUROVISION IMAGING (United States)
  • NIDEK CO., LTD. (Japan)
  • Haag-Streit Group (Switzerland)
  • Johnson & Johnson Vision Care Inc. (United States)
  • Novartis AG (Switzerland)
  • Topcon Corporation (Japan)
  • KARL STORZ SE & Co. KG (Germany)
  • Centervue SpA, (Italy)
  • Eyenuk Inc (United States)
  • Imagine Eyes (France)
  • HealPros, LLC. (United States)
  • Optos (United Kingdom)
  • Zeiss Group (Germany)
  • Biogen (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 232 Pages 56 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Retinal Detachment- Market Quantitative research analysis
Global Retinal Detachment- Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Retinal Detachment- market are Alcon Laboratories Inc. (Switzerland), Bausch Health Companies Inc. (Canada), Peek Vision Ltd. (United Kingdom), NEUROVISION IMAGING (United States), NIDEK CO., LTD. (Japan), Haag-Streit Group (Switzerland), Johnson & Johnson Vision Care Inc. (United States), Novartis AG (Switzerland), Topcon Corporation (Japan), KARL STORZ SE & Co. KG (Germany), Centervue SpA, (Italy), Eyenuk Inc (United States), Imagine Eyes (France), HealPros, LLC. (United States), Optos (United Kingdom), Zeiss Group (Germany) and Biogen (United States), to name a few.
"The trend towards minimally invasive procedures continues to grow in the retinal detachment industry" is seen as one of major influencing trends for Retinal Detachment- Market during projected period 2023-2030.

Know More About Global Retinal Detachment- Market Report?

Have a Query? Click Here

Other Related Reports

Autism Disorder and Treatment- Comprehensive Study by Therapy (Antipsychotic Drugs, Selective Serotonin Reuptake Inhibitors (SSRI) /Antidepressants, Stimulants, Sleep Medications, Others), Type (Auti...
$ 3800
Bone Pain Treatment- Comprehensive Study by Treatment (Therapies, Surgery, Antibiotics, Others), Indication (Injury, Trauma, Bone Tumour, Infection, Others), End User (Hospital, Speciality Clinics, ...
$ 3800
Hemianopsia- Comprehensive Study by Type (Bitemporal, Homonymous, Heteronymous, Superior, Inferior, Others), Treatment (Vision Restoration Therapy (VRT), Visual Field Expander Aid, Visual Auditory Tr...
$ 3800
Allergic Rhinitis- Comprehensive Study by Type (Perennial Allergic Rhinitis, Seasonal Allergic Rhinitis, Occupational Allergic Rhinitis), Treatment (Immunotherapy, Antihistamines, Decongestant, Corti...
$ 3800
Anophthalmia and Microphthalmia Comprehensive Study by Application (Hospitals, Speciality Clinics, Research Center, Others), Treatment (Surgical Interventions, Prosthetic Devices, Gene Therapy, Pharm...
$ 3800
Thyroid Disorder Therapy Comprehensive Study by Drug Type (Kinase Inhibitors, Anthracyclines, Beta-Blockers, Others), Disease Type (Hypothyroidism, Hyperthyroidism, Goiter, Hashimoto Disease, Others)...
$ 3800